2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
78
Neoplasms
69
Prostatic Neoplasms
51
Colorectal Neoplasms
45
Lung Neoplasms
39
Carcinoma, Non-Small-Cell Lung
28
Hematologic Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Head and Neck Neoplasms
20
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
15
Multiple Myeloma
15
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Glioblastoma
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Gastrointestinal Neoplasms
9
Colonic Neoplasms
9
Melanoma
8
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Interventions
Temozolomide
2
Lenalidomide
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Cyclophosphamide
2
venetoclax
1
trametinib
1
toripalimab
1
tafasitamab
1
sonidegib
1
ribociclib
1
fludarabine
1
etoposide phosphate
1
camrelizumab
1
brivanib
1
apatinib
1
acalabrutinib
1
Vincristine
1
Valganciclovir
1
Thiotepa
1
Therapeutics
1
Telemedicine
1
Tamoxifen
1
Surveys and Questionnaires
1
Standard of Care
1
Rituximab
1
Radiotherapy
1
R-CHOP protocol
1
Patient Navigation
1
N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pyloric Stenosis, Hypertrophic
×
Standard of Care
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled